Q-linea (QLINEA) Q4 2024 earnings summary

Executive summary

• 2024 marked a pivotal year with FDA clearance, US launch, and commercial team expansion, positioning the company as a leader in rapid AST instrument placements and clinical coverage.

• The company transitioned from development to commercialization, reallocating resources, reducing costs, and maintaining technical leadership.

• Q-linea led the global rapid AST market with the highest number of placed instruments and clinical evidence, supported by early adopters and channel partners in Europe, the US, and the Middle East.

• The addressable market is significant, with over 25 million inpatient tests annually and a focus on high-risk populations such as sepsis and oncology patients.

• First US commercial sale achieved in January 2025, nine months after FDA approval.

Financial highlights

• No capital sales of ASTAR in Q4; revenue for the year was on par with 2023, with ASTAR and other income each contributing about 50%.

• Net sales for Q4 2024 were SEK 0.2 million, with FY 2024 income at SEK 5.8 million, primarily from reagent rental contracts in Italy.

• Cost-cutting and restructuring programs led to a SEK 60 million annual OpEx reduction, with headcount dropping from 127 to 94.

• End-of-year cash and cash equivalents stood at SEK 25.7 million, with significant loans and bridge financing utilized and partially repaid.

• Rights issue and directed share issue raised approximately SEK 216 million before costs, increasing equity by SEK 205 million and liquidity by SEK 93 million due to loan netting.

Outlook and guidance

• 2025 is expected to see accelerated commercial progress in both the US and Europe, with more contracts and instrument placements anticipated.

• The company targets breakeven by 2027 and expects to provide more contract value and margin details as market traction increases.

• Ongoing and upcoming clinical studies will provide real-world evidence and health economic impact data, supporting further adoption.

• Additional financing of SEK 80 million is required to secure going concern; full warrant subscription in May could provide SEK 105 million net.

• Board is optimistic about securing further funding through warrants and grants, but notes uncertainty if not achieved.